Treatment results and prognostic factors in inoperable carcinoma of the cervix treated with external plus high dose brachytherapy

• Published in: Cancer letters 1999-02, Vol.136 (1), p.17-26
• Main Authors: Garipagaoglu, Melahat, Yalvac, Serdar, Kose, M.Faruk, Tulunay, Gokhan, Kayikcioglu, Fulya, Çakmak, Ahmet, Haberal, Ali, Boran, Nurettin, Adli, Mustafa, Hayran, Mutlu
• Format: Article
• Language: English
• Subjects: Adult; Biological and medical sciences; Brachytherapy - adverse effects; Brachytherapy - methods; Female; Follow-Up Studies; High dose rate brachytherapy; Humans; Inoperable cervical carcinoma; Lymphatic Metastasis; Medical sciences; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prognostic criteria; Radiation therapy and radiosensitizing agent; Radiotherapy - adverse effects; Radiotherapy - methods; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome; Treatment with physical agents; Treatment. General aspects; Tumors; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - radiotherapy
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/S0304-3835(98)00293-6

Patients with inoperable carcinoma of the cervix treated with external plus high dose rate brachytherapy (HDRB), between 1988 and 1995 were evaluated retrospectively. According to stage, 5 year survival rates were 67.3% in stage IIb and 52.6% in stage III ( P=0001) and disease free survival (DFS) rates were 54.0% in stage IIb and 43.9% in stage III ( P=0.01). The following parameters were studied: age; stage; external beam dose; brachytherapy dose; total dose to point A; tumor mass; tumor response rate; bilateral or unilateral invasion of parametria in stage IIb; and bilateral or unilateral invasion of pelvic wall in stage IIIb; and the existence of hydronephrosis. The only significant parameter of 5 year survival and local control was tumor mass ( P=0.003).